Neurizon Taps A$5m in Convertible Note Funding From Obsidian

Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.

Neurizon Therapeutics has issued a cleansing notice ahead of the expected issuance of 3,575,500 unquoted convertible notes to New York-based Obsidian Global GP under a two-year, up to A$20 million funding facility. The first A$5 million drawdown will increase Neurizon’s cash reserves while also raising its secured indebtedness, with the notes convertible into fully paid ordinary shares, implying future equity dilution but providing immediate funding flexibility for ongoing operations.

The company confirms shareholder approval for the first tranche and indicates that remaining conditions precedent for the issue are either satisfied or will be met on the day of issuance. Upon conversion of the notes, Neurizon’s share count will rise and its debt will fall by the face value of notes converted, shaping its capital structure and giving the company scope to manage liquidity and balance-sheet strength as it progresses its activities.

The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is an ASX-listed biotechnology company focused on developing therapeutic treatments in the life sciences sector. The company operates from Melbourne and accesses capital markets to fund its research and development programs, utilising structured financing instruments such as convertible note facilities to support its growth plans.

Average Trading Volume: 532,927

Technical Sentiment Signal: Sell

Current Market Cap: A$66.8M

For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.